Full Press Release Details
Altimmune Announces FDA Clearance of AdCOVID IND Application.
ALT
Altimmune Announces FDA Clearance of AdCOVID IND Application
Key Takeaway: Altimmune Announces FDA Clearance of AdCOVID IND Application
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight